For example, a 65-year-old postmenopausal woman with an estrogen receptor positive, HER2 negative, 1.5 cm breast cancer with no nodal involvement, the 10 year absolute OS benefit from adjuvant endocrine therapy is 0.9% per the PREDICT model [20]. This evidence concerns the gene ESR1 and breast carcinoma.